AHK-Cu vs SS-31 (Elamipretide)
Side-by-side comparison of key properties, dosing, and research.
Skin & CosmeticAnti-Aging & Longevity
AHK-CuAnti-Aging & Longevity
SS-31 (Elamipretide)- Summary
- AHK-Cu is a copper tripeptide composed of alanine, histidine, and lysine chelated to copper. Distinct from GHK-Cu, AHK-Cu exhibits strong affinity for hair follicle receptors and demonstrates potent hair growth stimulation alongside wound healing and skin regeneration properties.
- SS-31 (Elamipretide) is a synthetic mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane and protects cardiolipin from oxidative damage. It is one of the most promising mitochondrial longevity compounds, studied in clinical trials for heart failure, renal disease, and age-associated mitochondrial dysfunction.
- Half-Life
- Hours (topical, variable by formulation)
- ~2–5 hours
- Admin Route
- Topical, Scalp application, Subcutaneous (research)
- SubQ
- Research
- —
- —
- Typical Dose
- 0.01–0.1% concentration
- 5–10 mg
- Frequency
- Once or twice daily
- Daily to several times per week
- Key Benefits
- Stimulates hair follicle growth and reduces shedding
- Increases dermal papilla cell proliferation
- Promotes wound healing and skin regeneration
- Antioxidant protection via superoxide dismutase activation
- Improves skin elasticity and firmness
- Supports collagen and elastin production
- Restores mitochondrial function and ATP production
- Protects inner mitochondrial membrane cardiolipin
- Reduces mitochondrial reactive oxygen species (ROS)
- Improves exercise capacity and reduces fatigue
- Cardioprotective — studied in heart failure trials
- Renoprotective — reduces ischemic kidney injury
- Anti-aging via mitochondrial preservation
- Potential in neurodegenerative disease prevention
- Side Effects
- Generally well-tolerated topically
- Mild scalp irritation or redness in sensitive individuals
- Possible temporary hair shedding phase at treatment initiation
- Copper accumulation with excessive systemic use (rare)
- Injection site irritation
- Nausea (rare)
- Generally well-tolerated in clinical trials
- Stacks With
- —
- —